jpm_asset_mgmt
  • Investment Strategies

    Investment Options

    • Alternatives
    • Beta Strategies
    • Equities
    • Fixed Income
    • Global Liquidity
    • Multi-Asset Solutions

    Capabilities & Solutions

    • ETFs
    • Pension Strategy & Analytics
    • Global Insurance Solutions
    • Outsourced CIO
    • Sustainable Investing
  • Insights

    Market Insights

    • Market Insights Overview
    • Eye on the Market
    • Guide to the Markets
    • Guide to Alternatives
    • Market Updates

    Portfolio Insights

    • Portfolio Insights Overview
    • Alternatives
    • Asset Class Views
    • Currency
    • Equity
    • ETF Perspectives
    • Fixed Income
    • Long-Term Capital Market Assumptions
    • Sustainable Investing

    Retirement Insights

    • Retirement Insights Overview
    • Essential Elements of a Sound Retirement System
    • Building Better Retirement Portfolios
  • Resources
    • Center for Investment Excellence Podcasts
    • Insights App
    • Library
    • Multimedia
  • About us
  • Contact Us
Skip to main content
  • English
  • Role
  • Country
  • Client Reporting
Search
Menu
CLOSE
Search
  1. Home
  2. Insights
  3. Market Insights
  4. Eye on the Market
  5. Coronavirus research

  • Share
  • LinkedIn Twitter Facebook
  • Email
  • Print
  • Actions
  • LinkedIn Twitter Facebook
    Email Print

Coronavirus (COVID-19) research

April 2021

Michael Cembalest

This compilation includes all of our research to-date on the coronavirus. High frequency charts on infection, mortality, economic and market data are updated as data becomes available, usually on a daily basis.

What’s new: Early tracking of variants and vaccine efficacy (Section 4); Vaccination update by country and US state (Section 4); Reinfection risks in previously infected populations (Section 5).

To hear more of Michael Cembalest’s thoughts on global markets and the economy, explore previous versions of Eye on the Market:

READ MORE BY MICHAEL CEMBALEST

Access Michael Cembalest’s COVID Charts of the Week:

VIEW NOW

Our research to-date on the coronavirus:


1. US spending, mobility, and production tracker ›
2. COVID global infection, hospitalization and mortality tracker ›
3. COVID tracker: countries and states ›
4. COVID vaccination update and drug development ›
5. COVID: reinfection, antibodies, T-cell immune memory and survivor impacts ›

1. US spending, mobility, and production tracker

  • High frequency tracking (manufacturing, retail, air travel, geolocation, oil, hotels, housing, etc.)
  • Office utilization rates and mobility
  • Real time credit and debit spending data

READ MORE


2. COVID global infection, hospitalization and mortality tracker

  • Commentary and charts on the latest COVID trends by country and region
  • Global and regional snapshots, comparisons of largest countries and US states
  • How lethal is COVID, and for whom?

READ MORE


3. COVID tracker: countries and states 

  • Country and state specific charts on Infection, hospitalization and mortality

READ MORE


4. COVID vaccination update

  • Early tracking of variants and vaccine efficacy
  • Where does herd immunity kick in?
  • Vaccination update by country and US state
  • How mRNA vaccines, vector vaccines and traditional vaccine types work

READ MORE


5. COVID: reinfection, antibodies, T-cell immune memory and survivor impacts 

  • Reinfection risks in previously infected populations
  • COVID health impacts on survivors
  • How virus testing and antibody testing work 
  • Pre-existing T-cell immune memory and COVID
  • The issue of falling antibody levels in convalescing patients
  • The latest news on anti-virals, monoclonal antibodies, convalescent plasma and corticosteroids

READ MORE

This compilation incorporates research and feedback from the Johns Hopkins University Center for Health Security, Harvard Medical School, the University of Toronto Dalla Lana School of Public Health, Washington University Biomedical Sciences Department, the La Jolla Institute for Immunology, the Imperial College of London Department of Infectious Disease Epidemiology and the National Institute of Allergy and Infectious Diseases at the National Institutes of Health.


0903c02a8283f910

Listen and Subscribe

 

Listen on Apple Podcasts ›

Subscribe to RSS Feed ›

   

 

Get the latest commentaries in your inbox ›

Follow Michael Cembalest on LinkedIn ›

Markets Volatility Eye on the Market
J.P. Morgan Asset Management

  • About us
  • Investment stewardship
  • Privacy policy
  • Cookie policy
  • Binding corporate rules
  • Sitemap
Opens LinkedIn site in new window
J.P. Morgan

  • J.P. Morgan
  • JPMorgan Chase
  • Chase

READ IMPORTANT LEGAL INFORMATION. CLICK HERE >

The value of investments may go down as well as up and investors may not get back the full amount invested.

Copyright 2021 JPMorgan Chase & Co. All rights reserved.